Skip To Main Content

Inspiration and Innovation

Get inspired and stay on the cutting edge of innovation with these resources.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
Relationship Between LDL-C LLTs and Risk of Stroke

Relationship Between LDL-C LLTs and Risk of Stroke

Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement

Management of athletes and active people with diabetes - The American Medical Society for Sports Medicine (AMSSM) scientific statement

VTE Prophylaxis in Surgical Patients

VTE Prophylaxis in Surgical Patients

Odyssey outcomes - mortality

Odyssey outcomes - mortality

Acute Medical Illness: Advanced Age Alone Predicts Venous Thromboembolism Similar to Existing Risk Assessment Models

Acute Medical Illness: Advanced Age Alone Predicts Venous Thromboembolism Similar to Existing Risk Assessment Models

ESC Lp(a) in Clinical practice EAS Consensus statement

ESC Lp(a) in Clinical practice EAS Consensus statement

Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs

Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs

Galimberti F, et al. Poster presented at the 91st European Atherosclerosis Society congress (EAS) 2023.

Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early

Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early

ESC/EAS 2019 Guidelines for the management of dyslipidaemias

ESC/EAS 2019 Guidelines for the management of dyslipidaemias

Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery

Caprini Score Responses to Prevent VTE in Patients Undergoing Varicose Vein Surgery

VTE Risk Assessment in Surgical Patients

VTE Risk Assessment in Surgical Patients

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.